{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:39:49Z","timestamp":1793353189859,"version":"4.5.0"},"reference-count":35,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prognosis and disease severity in cystic fibrosis (CF) are linked to declining lung function. To characterise lung function by the number of adults in countries with different levels of Gross National Income (GNI), data from the European Cystic Fibrosis Society Patient Registry were utilised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Annual data including age, forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), anthropometry, genotype, respiratory cultures and CF-related diabetes (CFRD) were retrieved between 2011 and 2021. All countries were stratified into GNI per capita to reflect differences within Europe.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A consistent improvement in FEV\n                      <jats:sub>1<\/jats:sub>\n                      % pred and survival was observed among the 47\u2009621 people with CF (pwCF), including subjects with chronic\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      infection, CFRD and\/or undernutrition. Mean values of FEV\n                      <jats:sub>1<\/jats:sub>\n                      % pred changed from 85% to 94.2% for children and from 63.6% to 74.7% for adults. FEV\n                      <jats:sub>1<\/jats:sub>\n                      % pred further increased among those carrying the F508del mutation in 2021, when elexacaftor\/tezacaftor\/ivacaftor was available. The number of adult pwCF increased from 13\u2009312 in 2011 to 21\u2009168 in 2021, showing a 60% increase. PwCF living in European lower income countries did not demonstrate a significant annual increase in FEV\n                      <jats:sub>1<\/jats:sub>\n                      % pred or in the number of adults.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This pan-European analysis demonstrates a consistent improvement in FEV\n                      <jats:sub>1<\/jats:sub>\n                      % pred, number of adult pwCF and survival over the last decade only in European higher and middle income countries. Urgent action is needed in the lower income countries where such improvement was not observed. The notable improvement observed in pwCF carrying the F508del mutation emphasises the need to develop treatments for all CF mutations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01241-2023","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:35:12Z","timestamp":1706787312000},"page":"2301241","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Cystic fibrosis in Europe: improved lung function and longevity \u2013 reasons for cautious optimism, but challenges remain"],"prefix":"10.1183","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-386X","authenticated-orcid":false,"given":"Eitan","family":"Kerem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-2757","authenticated-orcid":false,"given":"Annalisa","family":"Orenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Adamoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-2054","authenticated-orcid":false,"given":"Elpis","family":"Hatziagorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-9482","authenticated-orcid":false,"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024102103222192000_63.3.2301241.1","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3390\/ijerph15092020","article-title":"Cystic fibrosis mortality in childhood. Data from European Cystic Fibrosis Society Patient Registry","volume":"15","author":"Zolin","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"2024102103222192000_63.3.2301241.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2005.01.001"},{"key":"2024102103222192000_63.3.2301241.3","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20023"},{"key":"2024102103222192000_63.3.2301241.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00056507"},{"key":"2024102103222192000_63.3.2301241.5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2017.01.002","article-title":"Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher","volume":"16","author":"Szczesniak","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.6","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/ppul.25075","article-title":"Drug development for cystic fibrosis","volume":"56","author":"Sanders","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2024102103222192000_63.3.2301241.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00196314"},{"key":"2024102103222192000_63.3.2301241.8","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-81"},{"key":"2024102103222192000_63.3.2301241.9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jcf.2022.11.001","article-title":"Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis","volume":"22","author":"Kerem","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2022.07.015","article-title":"Disease severity of people with cystic fibrosis carrying residual function mutations: data from the ECFS Patient Registry","volume":"22","author":"Mei-Zahav","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.11","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00449-2022"},{"key":"2024102103222192000_63.3.2301241.12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2019.08.006","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis \u2013 data from the European Cystic Fibrosis Society Patient Registry","volume":"19","author":"Hatziagorou","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00166412"},{"key":"2024102103222192000_63.3.2301241.14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.chest.2015.08.021","article-title":"Disparities in cystic fibrosis care and outcome: socioeconomic status and beyond","volume":"149","author":"Kerem","year":"2016","journal-title":"Chest"},{"key":"2024102103222192000_63.3.2301241.15","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/ppul.24434","article-title":"The demographics of adverse outcomes in cystic fibrosis","volume":"54","author":"McGarry","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2024102103222192000_63.3.2301241.16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/17476348.2016.1196140","article-title":"Socioeconomic status and health outcomes: cystic fibrosis as a model","volume":"10","author":"Oates","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"2024102103222192000_63.3.2301241.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(02)00141-8"},{"key":"2024102103222192000_63.3.2301241.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2024102103222192000_63.3.2301241.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.009"},{"key":"2024102103222192000_63.3.2301241.20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02288-2020"},{"key":"2024102103222192000_63.3.2301241.23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2020.02.004","article-title":"Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis","volume":"19","author":"Oates","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1513\/AnnalsATS.202010-1274ED","article-title":"Social inequities and cystic fibrosis outcomes: we can do better","volume":"18","author":"Oates","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2024102103222192000_63.3.2301241.25","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.6.9912100"},{"key":"2024102103222192000_63.3.2301241.26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.111.4.e333"},{"key":"2024102103222192000_63.3.2301241.27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S2213-2600(13)70002-X","article-title":"The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study","volume":"1","author":"Taylor-Robinson","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024102103222192000_63.3.2301241.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201009-1478CI"},{"key":"2024102103222192000_63.3.2301241.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(05)80016-5"},{"key":"2024102103222192000_63.3.2301241.30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jcf.2014.03.008","article-title":"Standards of care for cystic fibrosis ten years later","volume":"13","author":"Castellani","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2024102103222192000_63.3.2301241.32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11606-017-4199-3","article-title":"Cultural issues in medication adherence: disparities and directions","volume":"33","author":"McQuaid","year":"2018","journal-title":"J Gen Intern Med"},{"key":"2024102103222192000_63.3.2301241.33","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2007.55"},{"key":"2024102103222192000_63.3.2301241.34","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200953"},{"key":"2024102103222192000_63.3.2301241.35","unstructured":"European Medicines Agency . Qualification Opinion 4. The European Cystic Fibrosis Society Patient Registry (ECFSPR). 2018. www.ema.europa.eu\/documents\/regulatory-procedural-guideline\/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr_en.pdf Date last accessed: 14 January 2024."}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01241-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:17:23Z","timestamp":1740363443000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01241-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1183\/13993003.01241-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01241-2023","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s10942-025-00611-3","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}